COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03RIX
|
|||
Drug Name |
Sirukumab
|
|||
Synonyms |
Sirukumab (USAN); Sirukumab (genetical recombination) (JAN); D10080; 1194585-53-9
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Other Indication | Rheumatoid arthritis | Phase 3 | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
PubChem Substance ID |
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN interleukin 6 (IL6) | Target Info | Inhibitor | [3], [4] |
Sirukumab is a humanized antibody targeting interleukin-6, which is elevated in COVID-19 and is responsible for the lethal complications such as cytokine release syndrome of COVID-19. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04380961) A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19. U.S. National Institutes of Health. | |||
2 | ClinicalTrials.gov (NCT01689532) A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine. U.S. National Institutes of Health. | |||
3 | Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90. | |||
4 | Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.